Keywords: teva, copaxone, relapses, avonex, israeli, pharmaceutical, major
Teva's Copaxone: "less relapses than Avonex"
Article | 12 June 2006
Israeli pharmaceutical major Teva says that relapsing-remitting multiple sclerosis patients failing Avonex (interferon beta-1a) therapy achieved significant reductions in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
